Clinical trialNCT05755386RecruitingPhase 3Interventional

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

SponsorNovartis PharmaceuticalsEnrollment106IC-MPGN

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

131 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Recruiting
Novartis Investigative Site
Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
CABA, Argentina
Recruiting
Novartis Investigative Site
Santa Fe, Argentina
Recruiting

Brazil

Novartis Investigative Site
Fortaleza, Ceará, Brazil
Recruiting
Novartis Investigative Site
Brasília, Federal District, Brazil
Withdrawn
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Recruiting
Novartis Investigative Site
Recife, Pernambuco, Brazil
Recruiting
Novartis Investigative Site
Natal, Rio Grande do Norte, Brazil
Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting
Novartis Investigative Site
Niterói, Rio de Janeiro, Brazil
Withdrawn
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Withdrawn
Novartis Investigative Site
Botucatu, São Paulo, Brazil
Recruiting
Novartis Investigative Site
Santo André, São Paulo, Brazil
Recruiting
Novartis Investigative Site
Sao Jose Rio Preto, São Paulo, Brazil
Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Withdrawn
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting
Novartis Investigative Site
Salvador, Brazil
Recruiting

Canada

Novartis Investigative Site
Etobicoke, Ontario, Canada
Recruiting
Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting

Czechia

Novartis Investigative Site
Prague, Czechia
Recruiting

Denmark

Novartis Investigative Site
Aarhus N, Denmark
Recruiting
Novartis Investigative Site
Copenhagen, Denmark
Recruiting

France

Novartis Investigative Site
Marseille, France
Recruiting
Novartis Investigative Site
Montpellier, France
Recruiting
Novartis Investigative Site
Paris, France
Recruiting
Novartis Investigative Site
Rennes, France
Recruiting
Novartis Investigative Site
Toulouse, France
Recruiting

Germany

Novartis Investigative Site
Munich, Bavaria, Germany
Recruiting
Novartis Investigative Site
Würzburg, Bavaria, Germany
Recruiting
Novartis Investigative Site
Dresden, Saxony, Germany
Recruiting
Novartis Investigative Site
Jena, Thuringia, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
Essen, Germany
Recruiting

91 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboIptacopan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Oct 2023
Primary completion: 27 Oct 2028
Completion: 31 May 2029
Last update posted: 13 Jul 2026
Registered enrollment: 106
Registry id: NCT05755386

Cross-registrations

EU-CTR / CTIS (EudraCT)2022-002328-11

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.